US prosecutors investigate tip about timing of Pfizer's Covid vaccine

The report said on Wednesday GSK's former head of vaccine development, Philip Dormitzer, had told his colleagues about the delay by Pfizer, where he worked before joining the British company

covid
Reuters
2 min read Last Updated : Mar 27 2025 | 5:19 PM IST
Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its Covid shot's success in 2020 until after that year's election, the Wall Street Journal reported, citing people familiar with the matter. 
The report said on Wednesday GSK's former head of vaccine development, Philip Dormitzer, had told his colleagues about the delay by Pfizer, where he worked before joining the British company. 
However, Dormitzer has disputed the claims of his former colleagues. 
"My Pfizer colleagues and I did everything we could to get the FDA's Emergency Use Authorization at the very first possible moment. Any other interpretation of my comments about the pace of the vaccine's development would be incorrect," Dormitzer told Reuters. 
The WSJ report said the US Attorney's Office for the Southern District of New York, which includes Manhattan, is taking a closer look at GSK's claims. 
"We cannot comment because we have not received any inquiry from authorities about a so-called 'delay,' but Pfizer remains ready, willing, and able to explain why any allegation of impropriety is utter nonsense," Pfizer told Reuters. 
U.S. President Donald Trump has claimed in the past that Pfizer sat on positive data from the vaccine's clinical trials, but there was no evidence. 
"We have consistently and transparently reiterated the facts and the timeline of the tireless work of scientists, regulators, and thousands of clinical trial volunteers who made the vaccine possible. Theories to the contrary are simply untrue," Pfizer said.
The U.S. Attorney's Office in Manhattan has interviewed at least two people, including a GSK executive who took notes of a conversation with Dormitzer, the report said. 
The prosecutors are planning more interviews in the coming days, the report said, adding that Pfizer officials have not yet been interviewed. 
GSK declined to comment, while the US Attorney's Office did not immediately respond to Reuters' requests for comments.
 
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :GSKPfizerPharma

First Published: Mar 27 2025 | 5:19 PM IST

Next Story